Characterizing the ILD (interstitial lung disease) Care Continuum Using Real World Evidence

Page last updated September 10, 2025

Study Design: Retrospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Patient partners or engagement
Principal Investigator: Aparna Swaminathan
Institution: Duke Clinical Research Institute
PCORnet® Network Partner: The Coordinating Center for PCORnet®
Funder: Genentech
Funding Date: 2022
Study Duration: 2022 – 2024
Participating PCORnet® Clinical Research Networks: GPC, INSIGHT, PaTH, STAR
Therapeutic Area: Pulmonology
Condition: Idiopathic Pulmonary Fibrosis (IPF)
Age Range: 18 Years and older (Adult,  Older Adult )
Status: Completed

Research Question(s): Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease, affecting over 3 million individuals worldwide and causing progressive lung function deterioration and death within a median of 3-5 years after diagnosis. This project will help to characterize the interstitial lung disease (ILD) patient care continuum across ILD subtypes.